BACKGROUND: Increased oxidative stress is thought to contribute to the pathophysiology of major depressive disorder (MDD), which is in part due to diminished levels of glutathione, the primary anti-oxidant of the brain. Oral administration of N-acetyl-cysteine (NAC) replenishes glutathione and has therefore been shown to reduce depressive symptoms. Proton magnetic spectroscopy ((1)H-MRS) that allows quantification of brain metabolites pertinent to both MDD and oxidative biology may provide some novel insights into the neurobiological effects of NAC, and in particular metabolite concentrations within the anterior cingulate cortex (ACC) are likely to be important given the key role of this region in the regulation of affect. OBJECTIVE: The aim of this study was to determine whether the metabolite profile of the ACC in MDD patients predicts treatment with adjunctive NAC versus placebo. METHODS: This study was nested within a multicentre, randomized, double-blind, placebo-controlled study of MDD participants treated withadjunctive NAC. Participants (n = 76) from one site completed the spectroscopy component at the end of treatment (12 weeks). Spectra from a single-voxel in the ACC were acquired and absolute concentrations of glutamate (Glu), glutamate-glutamine (Glx), N-acetyl-aspartate (NAA) and myo-inositol (mI) were obtained. Binary logistic regression analysis was performed to determine whether metabolite profiles could predict NAC versus placebo group membership. RESULTS: When predicting group outcome (NAC or placebo), Glx, NAA and mI were a significant model, and had 75% accuracy, while controlling for depression severity and sex. However, the Glu, NAA and mI profile was only predictive at a trend level, with 68.3% accuracy. For both models, the log of the odds of a participant being in the NAC group was positively related to NAA, Glx and Glu levels and negatively related to mI levels. CONCLUSION: The finding of higher Glx and NAA levels being predictive of the NAC group provides preliminary support for the putative anti-oxidative role of NAC in MDD.
RCT Entities:
BACKGROUND: Increased oxidative stress is thought to contribute to the pathophysiology of major depressive disorder (MDD), which is in part due to diminished levels of glutathione, the primary anti-oxidant of the brain. Oral administration of N-acetyl-cysteine (NAC) replenishes glutathione and has therefore been shown to reduce depressive symptoms. Proton magnetic spectroscopy ((1)H-MRS) that allows quantification of brain metabolites pertinent to both MDD and oxidative biology may provide some novel insights into the neurobiological effects of NAC, and in particular metabolite concentrations within the anterior cingulate cortex (ACC) are likely to be important given the key role of this region in the regulation of affect. OBJECTIVE: The aim of this study was to determine whether the metabolite profile of the ACC in MDDpatients predicts treatment with adjunctive NAC versus placebo. METHODS: This study was nested within a multicentre, randomized, double-blind, placebo-controlled study of MDDparticipants treated with adjunctive NAC. Participants (n = 76) from one site completed the spectroscopy component at the end of treatment (12 weeks). Spectra from a single-voxel in the ACC were acquired and absolute concentrations of glutamate (Glu), glutamate-glutamine (Glx), N-acetyl-aspartate (NAA) and myo-inositol (mI) were obtained. Binary logistic regression analysis was performed to determine whether metabolite profiles could predict NAC versus placebo group membership. RESULTS: When predicting group outcome (NAC or placebo), Glx, NAA and mI were a significant model, and had 75% accuracy, while controlling for depression severity and sex. However, the Glu, NAA and mI profile was only predictive at a trend level, with 68.3% accuracy. For both models, the log of the odds of a participant being in the NAC group was positively related to NAA, Glx and Glu levels and negatively related to mI levels. CONCLUSION: The finding of higher Glx and NAA levels being predictive of the NAC group provides preliminary support for the putative anti-oxidative role of NAC in MDD.
Authors: Shantel L Duffy; Jim Lagopoulos; Zoe Terpening; Simon J G Lewis; Ron Grunstein; Loren Mowszowski; Nathan Cross; Daniel F Hermens; Ian B Hickie; Sharon L Naismith Journal: Sleep Date: 2016-04-01 Impact factor: 5.849
Authors: Joshua D Rosenblat; Roger S McIntyre; Gilberto S Alves; Konstantinos N Fountoulakis; André F Carvalho Journal: Curr Neuropharmacol Date: 2015 Impact factor: 7.363
Authors: S M Cotton; M Berk; A Watson; S Wood; K Allott; C F Bartholomeusz; C C Bortolasci; K Walder; B O'Donoghue; O M Dean; A Chanen; G P Amminger; P D McGorry; A Burnside; J Uren; A Ratheesh; S Dodd Journal: Trials Date: 2019-11-28 Impact factor: 2.279
Authors: Ana Paula Vargas Visentin; Rafael Colombo; Ellen Scotton; Débora Soligo Fracasso; Adriane Ribeiro da Rosa; Catia Santos Branco; Mirian Salvador Journal: Oxid Med Cell Longev Date: 2020-04-14 Impact factor: 6.543